Press Release
Burlington, MA – June 16, 2008 –
HyperMed, Inc., the developer and manufacturer of hyperspectral diagnostic systems with
application in diabetic and vascular disease, today announces the appointment of Patrick T. McGloin
as Vice President of Marketing.
Mr. McGloin brings to HyperMed 14 years' experience in establishing product strategy for brand growth
and new product lines in the healthcare and medical technology sectors. He joins HyperMed from Hologic Inc.
(NASDAQ: HOLX), where he was Director of Marketing for the flagship $220M NovaSure franchise. In this role
he was responsible for the creation of the surgical strategy and oversaw the dramatic growth in revenue and
market share both before and after Cytyc Corporation's merger with Hologic in October of 2007.
In other roles Pat was Director of Marketing for Bard Endoscopic Technologies, a division of C.R. Bard, Inc.,
where he directed division strategy leading to subsequent global sales expansion and its sale to ConMed Corporation
in 2004. Pat has also held marketing positions in wound management at Johnson and Johnson as well as Nucryst
Pharmaceuticals, Inc. where he helped launch Acticoat, a unique burn and woundcare care technology. Pat holds a
BS degree in Business Administration from Bryant University and an MBA from Boston University.
Mark Carbeau, Chief Executive Officer and President of HyperMed, Inc. commented: "We are very enthusiastic to
add Pat to our team at HyperMed. Pat has a proven capability for the design and execution of strategy and rapid
sales growth with many of the same target customers in similar product categories. He is an ideal complement and
extension of our strong leadership team."
About Hyperspectral Technology and HyperMed
Hyperspectral Technology (HT) is a novel medical imaging modality that combines advanced optics with sophisticated
mathematical algorithms to identify subtle changes in composition from reflected light. The technology was developed
initially by the Department of Defense for use in aerial espionage and satellite surveillance.
HyperMed has pioneered the use of HT for medical applications. The Company's OxyVu™ system measures oxy-hemoglobin
and deoxy-hemoglobin to enable clinicians to assess tissue metabolism. The company's initial focus is on complications
of diabetes and peripheral arterial disease. Through a simple thirty-second non-invasive scan, a physician gains valuable
insights that aid in planning of advanced treatment interventions and surgery.
For more information about HyperMed and the OxyVu™ system, please visit the company's website at
www.hypermed-inc.com.
Press Contacts:
HyperMed, Inc.
Harriet Bridges
Marketing Manager
781-229-5900 x6019
hbridges@hypermed-inc.com
|
